Searchable abstracts of presentations at key conferences on calcified tissues
Bone Abstracts (2013) 1 PP162 | DOI: 10.1530/boneabs.1.PP162

1Philipps-University of Marburg, Universitatsklinikum Giessen und Marburg, Marburg, Germany; 2Urologische Klinik, Klinikum rechts der Isar der Technische Universitaet Muenchen, Muenchen, Germany; 3Novartis Pharma GmbH, BU Oncology, Nuernberg, Germany; 4Novartis Pharma GmbH, Biostatistics and Medical Writing, Nuernberg, Germany; 5Outpatient Center, Magdeburg, Germany.


Introduction: The prospective, single-arm, open-label ZOTECT study was designed to assess the effect of zoledronic acid (ZOL) on bone-marker levels and potential correlations with disease outcomes in bisphosphonate-naive patients with bone metastases.

Methods: Patients with bone metastases from prostate cancer (PC; n=301) or breast cancer (BC; n=99) who have not received bisphosphonates for ≥6 months were enrolled at 98 sites in Germany (from May 2006 to July 2008). Patients received ZOL (4 mg) i.v. every 4 weeks for 4 months, with a final follow-up at 12 months. The primary endpoint was change in bone marker levels at 12 months relative to baseline. Secondary assessments included skeletal-related event (SRE) rate, pain, quality of life (QoL), and prostate-specific antigen (PSA) levels. Endpoints were assessed using summary statistics by visit/tumor type and Kaplan–Meier analyses.

Results: ZOL treatment significantly decreased bone-marker levels vs baseline (amino-terminal propeptide of type I collagen (P1NP), C-terminal cross-linking telopeptide of type I collagen (CTX); P<0.0001), and this decrease was maintained through the final 1-year follow-up visit. Baseline P1NP and CTX levels correlated with the extent of bone disease (P<0.0001, each) and on-treatment decreases in marker levels. Skeletal disease burden and bone-marker levels were similar between PC and BC patients, and ZOL did not significantly influence osteoprotegerin/receptor activator of nuclear factor-κB ligand levels. During the 12-month period, only 13 SREs occurred in 11 patients. On-treatment bone-marker level changes did not correlate with SRE rate, pain scores, or QoL. Mean PSA levels were lower at study end (120 days; 92.5 μg/l) than at baseline (168.5 μg/l; Wilcoxon’s signed-rank test, P=0.27). In general, ZOL was well tolerated and adverse events were consistent with its established safety profile.

Conclusions: This study confirms that ZOL therapy significantly reduces bone turnover (measured as P1NP and CTX levels) in patients with bone metastases from PC or BC.

Volume 1

European Calcified Tissue Society Congress 2013

Lisbon, Portugal
18 May 2013 - 22 May 2013

European Calcified Tissue Society 

Browse other volumes

Article tools

My recent searches

No recent searches.